Prognostic Significance of the Systemic Inflammation Response Index in Gastrointestinal Malignancy Patients: A pooled Analysis of 10,091 Participants

Liang, Xian-Wen; Liu, Bing; Yu, Hai-Jing; Chen, Jia-Cheng; Cao, Zhi; Wang, Sheng-Zhong; Wu, Jin-Cai

doi:10.2217/fon-2023-0545

Cited by 2 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, as reported in a meta-analysis involving 3,187 patients, SIRI independently predicted the dismal OS of NPC [ 33 ]. In another meta-analysis including 30 studies, an increased SIRI was markedly related to poor OS and DFS in patients with gastrointestinal tumor patients [ 34 ]. According to Zhou et al.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis

Zhang,

Cheng

2024

Annals of Medicine

View full text Add to dashboard Cite

Background Many studies have explored the value of the systemic inflammation response index (SIRI) in predicting the prognosis of patients with breast cancer (BC); however, their findings remain controversial. Consequently, we performed the present meta-analysis to accurately identify the role of SIRI in predicting BC prognosis. Methods PubMed, Embase, Cochrane Library, and Web of Science databases were comprehensively searched between their inception and February 10, 2024. The significance of SIRI in predicting overall survival (OS) and disease-free survival (DFS) in BC patients was analyzed by calculating pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Results Eight articles involving 2,997 patients with BC were enrolled in the present study. According to our combined analysis, a higher SIRI was markedly associated with dismal OS (HR = 2.43, 95%CI = 1.42–4.15, p < 0.001) but not poor DFS (HR = 2.59, 95%CI = 0.81–8.24, p = 0.107) in patients with BC. Moreover, based on the pooled results, a high SIRI was significantly related to T3–T4 stage (OR = 1.73, 95%CI = 1.40–2.14, p < 0.001), N1–N3 stage (OR = 1.61, 95%CI = 1.37–1.91, p < 0.001), TNM stage III (OR = 1.63, 95%CI = 1.34–1.98, p < 0.001), and poor differentiation (OR = 1.25, 95%CI = 1.02–1.52, p = 0.028). Conclusion According to our results, a high SIRI significantly predicted poor OS in patients with BC. Furthermore, elevated SIRI was also remarkably related to increased tumor size and later BC tumor stage. The SIRI can serve as a novel prognostic biomarker for patients with BC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis

Zhang,

Cheng

2024

Annals of Medicine

View full text Add to dashboard Cite

show abstract

The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI‐RADS 3 lesions on multiparametric magnetic resonance imaging

Kayar,

Tokuc,

Ozsoy

et al. 2024

The Prostate

View full text Add to dashboard Cite

BackgroundThe diagnostic accuracy of suspicious lesions that are classified as PI‐RADS 3 in multiparametric prostate magnetic‐resonance imaging (mpMRI) is controversial. This study aims to assess the predictive capacity of hematological inflammatory markers such as neutrophil‐lymphocyte ratio (NLR), pan‐immune‐inflammation value (PIV), and systemic immune‐response index (SIRI) in detecting prostate cancer in PI‐RADS 3 lesions.Methods276 patients who underwent mpMRI and subsequent prostate biopsy after PI‐RADS 3 lesion detection were included in the study. According to the biopsy results, the patients were distributed to two groups as prostate cancer (PCa) and no cancer (non‐PCa). Data concerning age, PSA, prostate volume, PSA density, PI‐RADS 3 lesion size, prostate biopsy results, monocyte counts (109/L), lymphocyte counts (109/L), platelet counts (109/L), neutrophils count (109/L) were recorded from the complete blood count. From these data; PIV value is obtained by monocyte × neutrophil × platelet/lymphocyte, NLR by neutrophil/lymphocyte, and SIRI by monocyte number × NLR.ResultsSignificant variations in neutrophil, lymphocyte, and monocyte levels between PCa and non‐PCa patient groups were detected (p = 0.009, p = 0.001, p = 0.005 respectively, p < 0.05). NLR, PIV, and SIRI exhibited significant differences, with higher values in PCa patients (p = 0.004, p = 0.001, p < 0.001 respectively, p < 0.05). The area under curve of SIRI was 0.729, with a cut‐off value of 1.20 and with a sensitivity 57.70%, and a specificity of 68.70%.ConclusionSIRI outperformed NLR and PIV in detecting PCa in PI‐RADS 3 lesions, showcasing its potential as a valuable biomarker. Implementation of this parameter to possible future nomograms has the potential to individualize and risk‐stratify the patients in prostate biopsy decision.

show abstract

Prognostic Significance of the Systemic Inflammation Response Index in Gastrointestinal Malignancy Patients: A pooled Analysis of 10,091 Participants

Cited by 2 publications

References 54 publications

Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis

Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis

The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI‐RADS 3 lesions on multiparametric magnetic resonance imaging

Contact Info

Product

Resources

About